Neurocrine Biosciences (NBIX) Revenue (2010 - 2026)

Neurocrine Biosciences' Revenue history runs 16 years deep, the most recent figure standing at $814.5 million for Q1 2026.

• Quarterly Revenue rose 42.25% year-over-year to $814.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.1 billion (up 28.59% YoY) and the FY2025 annual result came in at $2.9 billion, up 21.45% from the prior year.
• Revenue was $814.5 million for Q1 2026 at Neurocrine Biosciences, up from $805.5 million in the prior quarter.
• Across five years, Revenue topped out at $814.5 million in Q1 2026 and bottomed at $20.0 million in Q2 2022.
• A 5-year average of $532.2 million and a median of $515.3 million in 2024 frame the typical range for Revenue.
• Annual changes were most pronounced in 2022 — Revenue plunged 93.08% — and 2023, when it jumped 2163.5%.
• Neurocrine Biosciences' Revenue stood at $412.0 million in 2022, then grew by 25.05% to $515.2 million in 2023, then grew by 21.84% to $627.7 million in 2024, then increased by 28.33% to $805.5 million in 2025, then grew by 1.12% to $814.5 million in 2026.
• Business Quant data shows NBIX's Revenue at $814.5 million in Q1 2026, $805.5 million in Q4 2025, and $794.9 million in Q3 2025.